Matisse Capital Procept Bio Robotics Corp Transaction History
Matisse Capital
- $192 Million
- Q4 2024
A detailed history of Matisse Capital transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Matisse Capital holds 22,285 shares of PRCT stock, worth $1.51 Million. This represents 0.94% of its overall portfolio holdings.
Number of Shares
22,285
Previous 10,468
112.89%
Holding current value
$1.51 Million
Previous $838,000
114.08%
% of portfolio
0.94%
Previous 0.41%
Shares
2 transactions
Others Institutions Holding PRCT
# of Institutions
297Shares Held
41.6MCall Options Held
203KPut Options Held
141K-
Vanguard Group Inc Valley Forge, PA5.14MShares$348 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$236 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.75MShares$118 Million0.05% of portfolio
-
Wellington Management Group LLP Boston, MA1.49MShares$101 Million0.02% of portfolio
-
Loomis Sayles & CO L P1.21MShares$81.6 Million0.12% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $3.01B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...